NeuroOne Medical Technologies Corporation (Nasdaq: NMTC), a medical technology company focused on improving surgical care for neurological disorders, announced on June 25, 2026, that its independent directors approved an equity award to a new employee under the company's 2021 Inducement Plan. The grant, effective June 24, 2026, was made as a material inducement for the individual to join NeuroOne and was disclosed in compliance with Nasdaq Listing Rule 5635(c)(4), which requires public announcement of awards not made under a stockholder-approved plan.
The new hire, who was not a previous employee or director of NeuroOne, received an option to purchase 10,000 shares of the company's common stock at an exercise price of $3.27 per share, the closing price on the grant date. The option has a ten-year term and vests over four years, with 25% vesting on June 24, 2027, and the remainder vesting in 12 equal quarterly installments thereafter, subject to continued employment and certain acceleration or forfeiture provisions.
This inducement grant underscores NeuroOne's strategy to attract key talent as it continues to develop and commercialize its electrode technology platform. The company markets four FDA-cleared product families: Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System (for brain), and OneRF® Trigeminal Nerve Ablation System. These solutions aim to reduce hospitalizations and surgical procedures while improving patient outcomes by offering both diagnostic and therapeutic functions.
NeuroOne is also engaged in research and development for drug delivery, basivertebral nerve ablation, and spinal cord stimulation programs. The company's focus on innovation in neurological care makes the recruitment of skilled personnel critical to its growth. The use of inducement grants allows NeuroOne to offer competitive compensation packages without requiring stockholder approval, as permitted under Nasdaq rules.
The announcement of this grant provides transparency to investors and the market regarding the company's equity compensation practices. For more information about NeuroOne and its technologies, visit nmtc1.com.
